ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2185

35 Years Follow-up of Primary Sjögren’s Disease: A Single Center Study

Lorena Montano-Tapia1, Resit Yildrim2, Ana Mafalda Abrantes3 and David Isenberg4, 1Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain, 2Eskişehir Osmangazi University I, Eskişehir, Turkey, 3Centro Hospitalar Universitario Lisboa Norte, Lisbon, Portugal, 4University College London, London, United Kingdom

Meeting: ACR Convergence 2023

Keywords: Mortality, Sjögren's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (2177–2194) Sjögren’s Syndrome – Basic & Clinical Science Poster II

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Primary Sjögren’s syndrome (pSS) is an autoimmune rheumatic disease characterized by lymphocytic infiltration of exocrine glands. Its clinical manifestations are heterogeneous. Currently, the evidence regarding the outcomes of the disease during a long term of follow-up is poor.
We studied a cohort of Sjogren’s syndrome patients followed for up to over 35 years to analyze their outcomes during the course of the disease.

Methods: A cohort of 232 patients who were diagnosed with pSS and under care in a single center (University College London Hospital) between 1984 and December 2022 were retrospectively screened. The authors reviewed case notes, computer records, and primary healthcare databases on an audit basis. Demographic features and clinical features were assessed, as well as the outcome, death, and cause of death. Statistical analysis using frequencies, univariant analysis (χ2 and Fisher’s tests), multivariant analysis, logistic regression, and bivariant analysis were performed.

Results: The mean age at diagnosis was 50.5 years (SD=14.78 years). The mean years of follow-up since diagnosis was 12.1 years (SD= 8.65); 48 patients (20.7%) were lost to follow-up at some point during the study period and 37 patients (20.1%) died during this period. Lymphoma developed in 20 patients. When compared with the rest of the patients, the incidence of glandular manifestations was significantly higher in the lymphoma group (11 [55%] vs 59 [37.8%]; p=0.005). In an independent multivariate regression analysis, parotid swelling at the time of diagnosis was found to be the most important predictive factor (p< 0.001). The majority of lymphomas developed < 15 years post-diagnosis. Death occurred in 37 patients (20%), with a mean age of 80.20 years old (SD=8.547). Infection was the commonest cause of death, followed by malignancy related.

Conclusion: In our very long-term follow-up of Sjogren’s patients, the main complication associated with the disease was related to lymphoma development, which invariably occurred during the first years after diagnosis. In contrast, in our cohort among the patients who died, the majority were over 70 years old, confirming that the disease is clearly compatible with a long-life expectancy. Infection was the commonest cause of death.

Supporting image 1

Table_1: General characteristics of primary SS patients

Supporting image 2

Table 2 – Comparison of characteristics between dead and alive patients with primary SS diagnosis


Disclosures: L. Montano-Tapia: None; R. Yildrim: None; A. Abrantes: None; D. Isenberg: None.

To cite this abstract in AMA style:

Montano-Tapia L, Yildrim R, Abrantes A, Isenberg D. 35 Years Follow-up of Primary Sjögren’s Disease: A Single Center Study [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/35-years-follow-up-of-primary-sjogrens-disease-a-single-center-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/35-years-follow-up-of-primary-sjogrens-disease-a-single-center-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology